Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H44O12 |
| Molecular Weight | 584.6525 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C6=CC(=O)OC6)[C@H](O)[C@H](O)[C@H]1O
InChI
InChIKey=LPMXVESGRSUGHW-HBYQJFLCSA-N
InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
| Molecular Formula | C29H44O12 |
| Molecular Weight | 584.6525 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB01092Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23761677
http://www.druginfosys.com/drug.aspx?drugcode=537&type=9
Sources: https://www.drugbank.ca/drugs/DB01092
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23761677
http://www.druginfosys.com/drug.aspx?drugcode=537&type=9
There is no available information about this compound
Originator
Sources: http://www.jbc.org/content/96/3/647.full.pdf
Curator's Comment: Ouabain was discovered and so named in 1888 by Amaud
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P50993 Gene ID: 477.0 Gene Symbol: ATP1A2 Target Organism: Homo sapiens (Human) Sources: http://www.selleckchem.com/products/ouabain.html |
41.0 nM [Ki] | ||
Target ID: P13637 Gene ID: 478.0 Gene Symbol: ATP1A3 Target Organism: Homo sapiens (Human) Sources: http://www.selleckchem.com/products/ouabain.html |
15.0 nM [Ki] | ||
Target ID: CHEMBL390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23621895 |
63.0 nM [IC50] | ||
Target ID: CHEMBL392 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23621895 |
37.0 nM [IC50] | ||
Target ID: P05023|||Q9UJ20 Gene ID: 476.0 Gene Symbol: ATP1A1 Target Organism: Homo sapiens (Human) Sources: https://www.drugbank.ca/drugs/DB01092 |
50.0 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Ouabain Approved UseOuabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias. |
|||
| Primary | Ouabain Approved UseOuabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias. |
|||
| Primary | Ouabain Approved UseOuabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias. |
|||
PubMed
| Title | Date | PubMed |
|---|---|---|
| Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. | 2010-07-01 |
|
| Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. | 2010-06 |
|
| Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain. | 2010-05 |
|
| The new targets of ouabain in retinal interneurons of Sprague-Dawley rats. | 2010-04-05 |
|
| DNA damage after intracerebroventricular injection of ouabain in rats. | 2010-02-26 |
|
| Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain. | 2010-02 |
|
| Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes. | 2010-01-01 |
|
| Upregulation of Na+ and Ca2+ transporters in arterial smooth muscle from ouabain-induced hypertensive rats. | 2010-01 |
|
| Effects of long-term ouabain treatment on blood pressure, sodium excretion, and renal dopamine D(1) receptor levels in rats. | 2010-01 |
|
| Extracellular signal regulated kinase 5 mediates signals triggered by the novel tumor promoter palytoxin. | 2009-12-01 |
|
| Animal model of mania induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain. | 2009-12 |
|
| Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells. | 2009-11-01 |
|
| The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models. | 2009-09 |
|
| Low-dose ouabain constricts small arteries from ouabain-hypertensive rats: implications for sustained elevation of vascular resistance. | 2009-09 |
|
| Intracellular potassium stabilizes human ether-à-go-go-related gene channels for export from endoplasmic reticulum. | 2009-04 |
|
| Activation of BKCa channels by nitric oxide prevents coronary artery endothelial dysfunction in ouabain-induced hypertensive rats. | 2009-01 |
|
| Chronic ouabain treatment induces vasa recta endothelial dysfunction in the rat. | 2009-01 |
|
| Response of sodium pump to ouabain challenge in human glioblastoma cells in culture. | 2009 |
|
| Ouabain treatment changes the role of endothelial factors in rat resistance arteries. | 2008-12-14 |
|
| Structural and functional characteristic of a model for deep-seated lacunar infarct in rats. | 2008-10-15 |
|
| The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats. | 2008-08 |
|
| ACTH-induced hypertension is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit. | 2008-07 |
|
| Chronic ouabain treatment enhances cardiac myosin ATPase activity in rats. | 2008-07 |
|
| Proteomics investigation of protein expression changes in ouabain induced apoptosis in human umbilical vein endothelial cells. | 2008-06-01 |
|
| Chronic ouabain treatment increases the contribution of nitric oxide to endothelium-dependent relaxation. | 2008-06 |
|
| Hepatocyte growth factor increases uptake of estradiol 17beta-D-glucuronide and Oatp1 protein level in rat hepatocytes. | 2008-02-02 |
|
| Endogenous brain Na pumps, brain ouabain-like substance and the alpha2 isoform in salt-dependent hypertension. | 2007-12 |
|
| Involvement of endogenous ouabain-like compound in the cardiac hypertrophic process in vivo. | 2007-03-13 |
|
| Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. | 2007-02 |
|
| Functional heterogeneity of the "transporter" of electrogenic ionic pump of the Lumbricus terrestris somatic myocyte membrane. | 2006-12 |
|
| [Ouabain-induced apoptosis of Jurkat cells correlates with activation of caspase-3 and regulation of Bcl-2 gene family]. | 2006-10 |
|
| [Changes in renal sodium transport during hypertension development in ouabain-hypertensive rats]. | 2006-10 |
|
| Ouabain-induced hypertension enhances left ventricular contractility in rats. | 2006-09-13 |
|
| [Contribution of endothelin and its receptors to ouabain-induced hypertension in rats]. | 2006-09 |
|
| Central and peripheral renin-angiotensin systems in ouabain-induced hypertension. | 2006-08 |
|
| Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: role of Na+/K+ ATPase. | 2006-07 |
|
| Alterations in structure and mechanics of resistance arteries from ouabain-induced hypertensive rats. | 2006-07 |
|
| Visual behavior of adult goldfish with regenerating retina. | 2006-02-12 |
|
| Ouabain at pathological concentrations might induce damage in human vascular endothelial cells. | 2006-02 |
|
| [Comparative study of properties of Na+, K+-ATPase and Mg2+-ATPase of the myometrium plasma membrane]. | 2005-12-13 |
|
| Sodium pump alpha2 subunits control myogenic tone and blood pressure in mice. | 2005-11-15 |
|
| [Comparative analysis of the cardiac glycosides action on the growth of the cardiac tissue explants]. | 2005-11 |
|
| [Renal sodium handling in ouabain-hypertensive rats]. | 2005-08 |
|
| Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. | 1992 |
|
| Identification and characterization of a ouabain-like compound from human plasma. | 1991-07-15 |
|
| Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991-01-01 |
|
| Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias. | 1990-09 |
|
| [Pharmacological studies of celiprolol: III. Effects of celiprolol on the cardiovascular system and renal function, and its antiarrhythmic effects]. | 1990-04 |
|
| Association of in vivo and in vitro propranolol levels in canine Purkinje fibers with antiarrhythmic effects. | 1977-07 |
|
| The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. | 1968-09 |
Patents
Sample Use Guides
0.004 mg/kg - IV, as Recommended Initial dose
24 mg 24 hourly PO, as Maintenance dose
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.selleckchem.com/products/ouabain.html
Ouabain (0.1 uM-1.0 uM) inhibits the Na+ pump and increases stored Ca2+ in cultured rat astrocytes.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:16 GMT 2025
by
admin
on
Mon Mar 31 18:21:16 GMT 2025
|
| Record UNII |
5ACL011P69
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
C01AC01
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
||
|
WHO-VATC |
QC01AC01
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D010042
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
472805
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
211-139-3
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
100000076204
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
5ACL011P69
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
3519
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL222863
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
439501
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
2004
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
4826
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
SUB14721MIG
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
7762
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
OUABAIN
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
DB01092
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
m8270
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
145798
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
25485
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
DTXSID0043765
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
630-60-4
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
m10252
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SOLVATE->ANHYDROUS | |||
|
TRANSPORTER -> SUBSTRATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |